NEW YORK, April 18 - Qiagen said today it has bought Xeragon for about $8 million as part of its goal of expanding its oligonucleotide business.

Qiagen paid for the deal by issuing 564,000 shares in exchange for all of the outstanding capital stock of Xeragon. Qiagen said it may issue an additional payment of up to $1.2 million in cash or stock if certain performance targets are met by next December.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.